Eris Lifesciences reports MAT revenue of ₹3,318 Cr
Eris Lifesciences released its Q1FY26 corporate presentation, reporting a Moving Annual Total revenue of ₹3,318 Cr for the period ending March 2026. The company highlighted its top-5 position in the anti-diabetes segment with a 6% market share and a 16% share in insulins. For FY27, Eris provided guidance for its Domestic Branded Formulations segment, targeting growth of 1.3x CVM growth on a base revenue of ₹2,778 Cr, with an EBITDA margin of 37%.
*this image is generated using AI for illustrative purposes only.
Eris Lifesciences disclosed its corporate presentation for Q1FY26, reporting a Moving Annual Total (MAT) revenue of ₹3,318 Cr for the period ending March 2026. The company emphasized its strong presence in the super-specialty segment, which accounts for 80% of its revenue, and its ranking among the top-20 Indian pharmaceutical companies.
The presentation, submitted in accordance with Regulation 30 of the SEBI (LODR) Regulations, 2015, was disseminated on the company's website. It outlines the company's operational performance and strategic positioning across domestic and international markets.
Domestic Branded Formulations Performance
Eris Lifesciences secured a top-5 market position by revenue in the anti-diabetes therapy segment with a 6% market share. The company holds a leading position in insulins (RHI and Glargine) with a 16% market share. Additionally, the brand Sundae achieved the #1 rank by sales volume in the first month of launch for Gx Semaglutide.
The company's commercial engine includes approximately 1,200 Medical Representatives (MRs) and 500 Managers. Eris also noted that its market share in the anti-diabetes segment expanded from 4.9% to 5.9% over the last two years.
International Business and Manufacturing
International business comprised 11% of the consolidated revenue in FY26, with products marketed in over 70 countries. The company operates state-of-the-art R&D and manufacturing facilities, including ANVISA and PIC/s accredited injectable units and WHO-GMP biologics units.
Financial Metrics and Guidance
The company provided guidance for its Domestic Branded Formulations (DBF) segment for FY27. The base revenue for FY26 stands at ₹2,778 Cr, with growth guidance set at 1.3x of Cardiovascular Metabolic (CVM) growth. The EBITDA margin is guided at 37%, similar to FY26 levels, with H2 margins expected to be higher than H1.
| Metric | Value |
|---|---|
| MAT Mar'26 Revenue | ₹3,318 Cr |
| FY26 DBF Base Revenue | ₹2,778 Cr |
| FY27 DBF Growth Guidance | 1.3x of CVM growth |
| FY27 DBF EBITDA Margin | 37% |
| International Business Revenue Share (FY26) | 11% |
| Anti-Diabetes Market Share | 6% |
| Insulins Market Share | 16% |
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.50% | +3.39% | +8.57% | -5.57% | -9.05% | +108.44% |
What specific strategies will Eris employ to sustain the early momentum of the Gx Semaglutide launch against potential competition?
How does the company plan to leverage its R&D capabilities to expand its super-specialty portfolio beyond the current anti-diabetes focus?
What are the key targets for increasing the international business revenue share beyond the current 11% of consolidated revenue?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
